Analyst Reco. Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
5.42 ^USD	+0.74%		+4.03%	-39.71%

May. 14	Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024	CI
May. 07	Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HC Wainwright Cuts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains Buy Rating	Feb. 22	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $8 From $13, Keeps Outperform, Speculative Risk	Feb. 16	MT
HC Wainwright Adjusts Price Target on Aurinia Pharmaceuticals to $15 From $14, Maintains Buy Rating	23-08-07	MT
RBC Boosts Price Target on Aurinia Pharmaceuticals to $13 From $11 Ahead of Q1 Report, Keeps Outperform, Speculative Risk	23-05-02	MT
HC Wainwright Adjusts Price Target on Aurinia Pharmaceuticals to $14 From $26, Maintains Buy Rating	22-11-07	MT
SVB Securities Adjusts Price Target on Aurinia Pharmaceuticals to $12 From $17, Maintains Outperform Rating	22-11-04	MT
Oppenheimer Downgrades Aurinia Pharmaceuticals to Perform From Outperform, Notes Continued Commercial Challenges	22-11-04	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $10 From $18, Maintains Outperform, Speculative Risk Rating	22-11-04	MT
US Futures Lower Following Rate Hike, Ahead of Jobless, PMI Data	22-11-03	MT
HC Wainwright Adjusts Aurinia Pharmaceuticals' Price Target to $26 from $30, Keeps Buy Rating	22-08-09	MT
SVB Financial Adjusts Aurinia Pharmaceuticals Price Target to $17 From $22, Maintains Outperform Rating	22-08-08	MT
Oppenheimer Adjusts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains Outperform Rating	22-08-05	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $18 From $22, Citing Potential Scenarios for '036 Patent; Outperform, Speculative Risk Kept	22-08-05	MT
Cantor Fitzgerald Assumes Aurinia Pharmaceuticals at Overweight with $25 Price Target	22-05-05	MT
HC Wainwright Adjusts Price Target on Aurinia Pharmaceuticals to $30 From $33, Reiterates Buy Rating	22-05-05	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $22 From $27, Maintains Outperform Rating, Speculative Risk Qualifier	22-04-28	MT
SVB Leerink Adjusts Aurinia Pharmaceuticals' Price Target to $22 from $30, Keeps Outperform Rating	22-03-08	MT
Oppenheimer Adjusts Aurinia Pharmaceuticals Price Target to $18 From $31, Maintains Outperform Rating	22-03-02	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $27 From $31, Maintains Outperform Rating With Speculative Risk Qualifier	22-03-01	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $31 From $34, Maintains Outperform-Speculative Risk Rating	22-02-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Analyst Reco.

Filters